Mandate

Vinge advises STARK Group with its acquisition of FagFlis Group

Vinge has advised STARK Group in connection with its acquisition of the Nordic tiles actor FagFlis Group with its Swedish operation FF Kakel AB. The group has conducted operations since 1981 and includes, in addition to the Swedish stores, approximately 30 facilities in Norway with total turnover of approximately NOK 750 million.

The transaction is estimated to be completed around the turn of the year 2022/2023, following approval by the Norwegian Competition Agency.

Vinge’s team consisted of, among others,  Jonas BergströmJoacim RydergårdEllinor Wargenbrant and Tobias Onegård Karlsson (M&A), Frida Ställborn (Real Estate), Hedvig Ekdahl (Commercial Contracts), Ebba Svenburg (Employment Law), Karl-Gustaw Tobola (Banking and Finance), Sebastian Örndahl and Adam Löfquist (Competition Law) and Anna Ekdahl Roos (Project Assistant).

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024